OptimizeRx’s (OPRX) Buy Rating Reaffirmed at Lake Street Capital

OptimizeRx (NASDAQ:OPRX)‘s stock had its “buy” rating reiterated by equities researchers at Lake Street Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $11.00 target price on the stock. Lake Street Capital’s price objective would suggest a potential upside of 122.67% from the stock’s previous close.

OPRX has been the subject of several other reports. Royal Bank of Canada decreased their price target on shares of OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. JMP Securities decreased their target price on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a research report on Thursday, November 14th. Barclays cut their price target on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, November 14th. B. Riley decreased their price objective on OptimizeRx from $17.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Stifel Nicolaus cut their target price on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, OptimizeRx has an average rating of “Moderate Buy” and a consensus price target of $9.19.

OptimizeRx Trading Up 2.3 %

Shares of OptimizeRx stock traded up $0.11 on Tuesday, reaching $4.94. 204,473 shares of the company’s stock were exchanged, compared to its average volume of 165,041. The firm’s 50-day moving average is $5.34 and its two-hundred day moving average is $7.73. The company has a market capitalization of $91.00 million, a P/E ratio of -3.71 and a beta of 1.34. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $16.65.

Insider Activity at OptimizeRx

In other news, CEO William J. Febbo bought 20,000 shares of OptimizeRx stock in a transaction dated Thursday, December 12th. The stock was purchased at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the purchase, the chief executive officer now directly owns 601,253 shares in the company, valued at $3,012,277.53. The trade was a 3.44 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On OptimizeRx

A number of institutional investors have recently added to or reduced their stakes in OPRX. Bank of New York Mellon Corp increased its position in shares of OptimizeRx by 9.9% during the second quarter. Bank of New York Mellon Corp now owns 111,719 shares of the company’s stock valued at $1,117,000 after acquiring an additional 10,041 shares during the last quarter. Rhumbline Advisers increased its position in shares of OptimizeRx by 9.2% during the 2nd quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock valued at $315,000 after purchasing an additional 2,658 shares during the last quarter. Rice Hall James & Associates LLC raised its stake in shares of OptimizeRx by 23.5% during the 2nd quarter. Rice Hall James & Associates LLC now owns 496,135 shares of the company’s stock worth $4,961,000 after purchasing an additional 94,253 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of OptimizeRx by 12.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 324,130 shares of the company’s stock worth $3,241,000 after buying an additional 35,957 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in OptimizeRx by 101.8% during the second quarter. Renaissance Technologies LLC now owns 142,146 shares of the company’s stock valued at $1,421,000 after buying an additional 71,700 shares during the period. 76.47% of the stock is owned by institutional investors.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.